iTeos Therapeutics (ITOS) said Thursday that it is deprioritizing inupadenant to "focus resources on other programs."
The company said it will present data from the dose escalation part of a a mid-stage trial evaluating inupadenant plus chemotherapy in non-small cell lung cancer at an event hosted by the European Society for Medical Oncology.
"While the initial signal for inupadenant's RP2D in the A2A-005 trial compared to chemotherapy alone is encouraging and supports its differentiated, insurmountable profile, we as well as our scientific and clinical advisory boards believe it does not meet sufficient level of clinical activity to warrant further investment," said iTeos chief executive officer Michel Detheux.
Detheux said the company will provide updates on its pipeline next year.
Shares of the company were up more than 2% in recent premarket activity.
Price: 8.50, Change: +0.20, Percent Change: +2.39
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.